
February 2, 2022

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Cadilahc

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated February 2, 2022 titled "**Zydus supplies the first consignment of its COVID-19 vaccine ZyCoV-D**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Zydus supplies the first consignment of its COVID-19 vaccine ZyCoV-D

Ahmedabad, India, 2 February, 2022

Zydus today announced that the company has started the supplies of its COVID-19 vaccine ZyCoV-D, to the Government of India against their order from its newly commissioned state-of-the-art, Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad. The group is also planning to make the vaccine available in the private market. ZyCoV-D is a three dose vaccine administered intradermally using the painless PharmaJet® needle free system, Tropis®, on day 0, day 28 and day 56.

The vaccine will be priced at Rs 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST.

Zydus VTEC manufactures the drug substance for the needle-free DNA Plasmid vaccine, ZyCoV-D. The manufacturing process and in process material transfers within the plant are automated.

Zydus has also entered into a definitive agreement with Shilpa Medicare Limited, a contract manufacturing organization to produce mutually agreeable doses of ZyCoV-D. The company also entered into an agreement with Enzychem Lifesciences of Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine.

About ZyCoV-D

ZyCoV-D is a Plasmid DNA vaccine which when administered produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.

About Zydus

The Zydus group is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.

For further information please contact :
The Corporate Communications Department

Zydus Group

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878